Summary:
- This article discusses the positive results from a Phase 2 clinical trial of Pfizer's new cancer drug, Atirmociclib, for the treatment of second-line metastatic breast cancer.
- Atirmociclib is a next-generation CDK4 inhibitor, a type of cancer drug that targets a specific protein involved in cell division and growth.
- The trial showed that Atirmociclib was effective in slowing the progression of metastatic breast cancer in patients who had previously received other treatments, suggesting it could be a promising new option for these patients.